Mahendra K. Singh
Mahendra K. Singh
Research Assistant Professor, Department of Surgery, University of Miami
Verified email at
Cited by
Cited by
NEDD9 promotes oncogenic signaling in mammary tumor development
E Izumchenko, MK Singh, OV Plotnikova, N Tikhmyanova, JL Little, ...
Cancer research 69 (18), 7198-7206, 2009
Molecular basis for HEF1/NEDD9/Cas-L action as a multifunctional co-ordinator of invasion, apoptosis and cell cycle
MK Singh, L Cowell, S Seo, GM O’Neill, EA Golemis
Cell biochemistry and biophysics 48 (1), 54-72, 2007
A novel Cas family member, HEPL, regulates FAK and cell spreading
MK Singh, D Dadke, E Nicolas, IG Serebriiskii, S Apostolou, A Canutescu, ...
Molecular biology of the cell 19 (4), 1627-1636, 2008
Deregulation of HEF1 impairs M-phase progression by disrupting the RhoA activation cycle
D Dadke, M Jarnik, EN Pugacheva, MK Singh, EA Golemis
Molecular biology of the cell 17 (3), 1204-1217, 2006
Mutational spectrum of K‐ras oncogene among Indian patients with gallbladder cancer
MK Singh, K Chetri, UB Pandey, VK Kapoor, B Mittal, G Choudhuri
Journal of gastroenterology and hepatology 19 (8), 916-921, 2004
Apolipoprotein B-100 XbaI gene polymorphism in gallbladder cancer
MK Singh, UB Pandey, UC Ghoshal, I Srivenu, VK Kapoor, G Choudhuri, ...
Human genetics 114 (3), 280-283, 2004
Enhanced genetic instability and dasatinib sensitivity in mammary tumor cells lacking NEDD9
MK Singh, E Izumchenko, AJ Klein-Szanto, BL Egleston, M Wolfson, ...
Cancer research 70 (21), 8907-8916, 2010
HEI10 negatively regulates cell invasion by inhibiting cyclin B/Cdk1 and other promotility proteins
MK Singh, E Nicolas, W Gherraby, D Dadke, S Lessin, EA Golemis
Oncogene 26 (33), 4825, 2007
Quantification of excision repair cross-complementing group 1 and survival in p16-negative squamous cell head and neck cancers
R Mehra, F Zhu, DH Yang, KQ Cai, JE Weaver, MK Singh, AS Nikonova, ...
Clinical Cancer Research 19 (23), 6633-6643, 2013
Total PSA and free PSA in patients with severe liver dysfunction
RD Mittal, MK Singh, C Selvaraju, G Choudhuri
Indian Journal of Urology 19 (2), 117, 2003
Gallbladder Cancer and Aflatoxin: Do We Have Sufficient Evidence?
MK Singh, VK Kapoor
Gastroenterology 154 (1), 259-260, 2018
Internet resources for the human geneticist.
SK Pal, MK Singh, GS Pandey, B Mittal
Evaluation of Minnelide as potential targeted therapy for triple negative breast cancer
MK Singh, S Shah, NS Sharma, B Giri, S Banerjee, A Saluja
Cancer Research 77 (13 Supplement), 5119-5119, 2017
Re: Dutta et al.—gallbladder cancer
MK Singh, G Choudhuri
The American journal of gastroenterology 98 (4), 936, 2003
Non surgical palliation of malignant obstructive jaundice in northern India: problems posed by gallbladder cancer (GBC)
G Choudhuri, MK Singh, K Chetri, A Kumar, L Peter, S Mohindra, TS Negi, ...
The American Journal of Gastroenterology 95 (9), 2474, 2000
Gastroenterology and the Internet.
MK Singh, SK Pal, VK Kapoor, G Choudhuri
Tropical gastroenterology: official journal of the Digestive Diseases …, 2000
Triptolide pro-drug decreases tumor burden and halts tumor progression in a murine model of acute myeloid leukemia
B Giri, S Banerjee, J George, S Modi, VK Gupta, MK Singh, V Dudeja, ...
Cancer Research 76 (14 Supplement), 3499-3499, 2016
NEDD9 is required for initiation of HER2/Neu-dependent mammary tumor development
JL Little, E Izumchenko, MK Singh, S Seo, M Kurokawa, BL Egleston, ...
Cancer Research 70 (8 Supplement), 3257-3257, 2010
Abstract B106: Nedd9 null status initially delays mammary tumor growth, then selects for hyper‐aggressive mammary tumors
MK Singh, E Izumchenko, AJP Klein‐Szanto, EA Golemis
Molecular Cancer Therapeutics 8 (12 Supplement), B106-B106, 2009
Abstract# 2087: HEF1/NEDD9/CasL is required for activation of oncogenic signaling pathways in mammary tumor development
E Izumchenko, O Plotnikova, M Singh, N Tikhmyanova, J Little, S Seo, ...
Cancer Research 69 (9 Supplement), 2087-2087, 2009
The system can't perform the operation now. Try again later.
Articles 1–20